FDA approves GSK RSV vaccine for adults 50 to 59

A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Primanews The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, [...]

Read More